Kiromic Biopharma IncOTCQB:KRBP
- LAST PRICE2.7100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.7200/ 1
- Ask / Lots3.0000/ 1
- Open / Previous Close0.0000 / 2.7100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Apr 24, 2024
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients, from 8:08AM ET on Wednesday Apr 24, 2024 by Dow Jones
8:08AM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 2, 2024
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial, from 8:18AM ET on Tuesday Apr 02, 2024 by Dow Jones
8:18AM ET on Tuesday Apr 02, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Kiromic Biopharma Inc | 3.5M | -0.1x | --- |
Revelation Biosciences Inc | 3.5M | 0.1x | --- |
Virpax Pharmaceuticals Inc | 3.4M | -0.2x | --- |
Biophytis SA | 3.3M | 0.0x | --- |
Atreca Inc | 3.4M | 0.0x | --- |
GeoVax Labs Inc | 3.4M | -0.1x | --- |
Company Information
Kiromic BioPharma, Inc. is a clinical-stage fully integrated biotherapeutics company using its DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. The Company is developing multi-indication allogeneic T cell therapies that exploit the natural potency of Gamma Delta T cells (GDTs) to target solid tumors. It has three product candidates: Deltacel non-engineered GDTs, expanded and activated with technology, Procel GDTs engineered with a PD-1 switch receptor and Isocel GDTs engineered with an anti-Mesothelin isoform 2 Chimeric Antigen Receptor. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf GDT cells and they are in the preclinical development stage. Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. It also has new technologies in development to support its end-to-end approach.
Contact Information
- Headquarters
- 7707 Fannin St., Suite 140HOUSTON, TX, United States 77054
- Phone
- 832-968-4888
- Fax
- 302-655-5049
Executives
- Non-Executive Independent Chairman of the Board
- Michael Nagel
- Interim Chief Executive Officer, Director
- Pietro Bersani
- Interim Chief Financial Officer and Principal Accounting
- Brian Hungerford
- Interim Chief Operating Officer, Chief Scientific Officer
- Leonardo Mirandola
- Chief of Staff
- Scott Dahlbeck
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 1.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-29.21 |
Book Value | $-8.91 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
